| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
|
Eur Heart J
|
2012
|
13.74
|
|
2
|
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2013
|
12.73
|
|
3
|
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
|
Eur Heart J
|
2011
|
10.52
|
|
4
|
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
|
Eur J Heart Fail
|
2012
|
10.38
|
|
5
|
Third universal definition of myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
8.59
|
|
6
|
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
|
Eur J Cardiovasc Prev Rehabil
|
2007
|
6.10
|
|
7
|
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).
|
Eur Heart J
|
2007
|
5.92
|
|
8
|
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
|
Eur Heart J
|
2013
|
5.23
|
|
9
|
Lipoprotein(a) as a cardiovascular risk factor: current status.
|
Eur Heart J
|
2010
|
4.31
|
|
10
|
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
|
Eur Heart J
|
2011
|
3.00
|
|
11
|
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
|
Atherosclerosis
|
2011
|
2.90
|
|
12
|
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
|
Eur J Cardiovasc Prev Rehabil
|
2007
|
2.70
|
|
13
|
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).
|
Atherosclerosis
|
2012
|
2.10
|
|
14
|
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).
|
Eur J Anaesthesiol
|
2010
|
1.92
|
|
15
|
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
|
Am J Cardiol
|
2008
|
1.88
|
|
16
|
Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease.
|
Am J Cardiol
|
2005
|
1.66
|
|
17
|
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
1.58
|
|
18
|
[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)].
|
G Ital Cardiol (Rome)
|
2013
|
1.57
|
|
19
|
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
|
Atherosclerosis
|
2011
|
1.51
|
|
20
|
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
|
Int J Behav Med
|
2012
|
1.51
|
|
21
|
[Less salt--more health. Croatian action on salt and health (CRASH)].
|
Lijec Vjesn
|
2009
|
1.41
|
|
22
|
[Omega-3 fatty acids have proven effects on the heart--the impact of GISSI-HF trial].
|
Lijec Vjesn
|
2009
|
1.39
|
|
23
|
[Guidelines for diagnostics and treatment of arterial hypertension. Practical recommendations of the Croatian Working Group for Hypertension. Consideration on the ESH-ESC 2007 guidelines].
|
Lijec Vjesn
|
2008
|
1.37
|
|
24
|
European guidelines on cardiovascular disease prevention in clinical practice: executive summary.
|
Atherosclerosis
|
2007
|
1.33
|
|
25
|
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
|
Diab Vasc Dis Res
|
2008
|
1.27
|
|
26
|
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.
|
Circulation
|
2013
|
1.13
|
|
27
|
Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology.
|
Eur Heart J
|
2010
|
1.11
|
|
28
|
Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey.
|
J Hypertens
|
2011
|
1.10
|
|
29
|
Population-level changes to promote cardiovascular health.
|
Eur J Prev Cardiol
|
2012
|
1.00
|
|
30
|
Dyslipidemias in the prevention of cardiovascular disease: risks and causality.
|
Curr Cardiol Rep
|
2012
|
0.98
|
|
31
|
Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
|
Croat Med J
|
2005
|
0.91
|
|
32
|
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
|
Fundam Clin Pharmacol
|
2012
|
0.87
|
|
33
|
Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population.
|
Croat Med J
|
2011
|
0.86
|
|
34
|
Variants of ESR1, APOE, LPL and IL-6 loci in young healthy subjects: association with lipid status and obesity.
|
BMC Res Notes
|
2009
|
0.85
|
|
35
|
Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy.
|
Eur J Prev Cardiol
|
2012
|
0.85
|
|
36
|
Diabetic dyslipidemia or 'diabetes lipidus'?
|
Expert Rev Cardiovasc Ther
|
2011
|
0.85
|
|
37
|
Abnormal systolic blood pressure during treadmill test and brachial artery flow-mediated vasodilatation impairment.
|
Coll Antropol
|
2007
|
0.83
|
|
38
|
Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology.
|
Clin Chem Lab Med
|
2007
|
0.83
|
|
39
|
Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.
|
Eur Heart J
|
2012
|
0.83
|
|
40
|
[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
|
Acta Med Croatica
|
2010
|
0.82
|
|
41
|
Risk factors for microvascular atherosclerotic changes in patients with type 2 diabetes mellitus.
|
Coll Antropol
|
2013
|
0.82
|
|
42
|
Mitochondrial myopathy associated with a novel 5522G>A mutation in the mitochondrial tRNA(Trp) gene.
|
Eur J Hum Genet
|
2012
|
0.82
|
|
43
|
Differences in risk factors for coronary heart disease in patients from continental and Mediterranean regions of Croatia.
|
Wien Klin Wochenschr
|
2008
|
0.81
|
|
44
|
Comorbidity, multimorbidity and personalized psychosomatic medicine: epigenetics rolling on the horizon.
|
Psychiatr Danub
|
2010
|
0.80
|
|
45
|
Management of overweight and obese patients with coronary heart disease across Europe.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
0.80
|
|
46
|
Effects of lipoprotein lipase and peroxisome proliferator-activated receptor-gamma gene variants on metabolic syndrome traits.
|
Coll Antropol
|
2013
|
0.80
|
|
47
|
Clinical study on the effect of simvastatin on paraoxonase activity.
|
Arzneimittelforschung
|
2007
|
0.79
|
|
48
|
New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
|
Eur J Cardiovasc Prev Rehabil
|
2011
|
0.79
|
|
49
|
Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats.
|
Acta Pharm
|
2005
|
0.78
|
|
50
|
Mutation detection in Croatian patients with familial hypercholesterolemia.
|
Ann Hum Genet
|
2012
|
0.78
|
|
51
|
Polypill is not a 'vaccine-like' solution for primary cardiovascular disease prevention in all parts of the world.
|
J Epidemiol Community Health
|
2013
|
0.78
|
|
52
|
Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data.
|
Psychiatr Danub
|
2007
|
0.78
|
|
53
|
A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease.
|
Coll Antropol
|
2012
|
0.77
|
|
54
|
Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins.
|
Croat Med J
|
2004
|
0.77
|
|
55
|
The burden of hyperlipidaemia and diabetes in cardiovascular diseases.
|
Fundam Clin Pharmacol
|
2007
|
0.76
|
|
56
|
[Salt--hidden poison in everyday meal].
|
Lijec Vjesn
|
2009
|
0.76
|
|
57
|
Spontaneous perforation of the small intestine, a novel manifestation of classical homocystinuria in an adult with new cystathionine beta-synthetase gene mutations.
|
Coll Antropol
|
2011
|
0.76
|
|
58
|
[Three-year-old boy--a homozygote for familiar hypercholesterolemia].
|
Lijec Vjesn
|
2007
|
0.76
|
|
59
|
Endogenous steroid sex hormones and atherosclerosis of retinal arteries in men.
|
Med Sci Monit
|
2009
|
0.75
|
|
60
|
[European practice guidelines on prevention of cardiovascular diseases: executive summary].
|
G Ital Cardiol (Rome)
|
2008
|
0.75
|
|
61
|
[Not Available].
|
Lijec Vjesn
|
2015
|
0.75
|
|
62
|
Guidelines on CVD prevention: confusing or complementary?
|
Eur J Prev Cardiol
|
2013
|
0.75
|
|
63
|
[A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia].
|
Lijec Vjesn
|
2006
|
0.75
|
|
64
|
[Gaucher disease--guidelines for diagnosis and management of adult patients].
|
Lijec Vjesn
|
2014
|
0.75
|
|
65
|
Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: A four-year follow-up.
|
Wien Klin Wochenschr
|
2010
|
0.75
|
|
66
|
[Characteristics of hyperhomocysteinemia in dialysis patients].
|
Acta Med Croatica
|
2006
|
0.75
|
|
67
|
[Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
|
Lijec Vjesn
|
2003
|
0.75
|
|
68
|
Statins in heart failure - a failure?
|
Nutr Metab Cardiovasc Dis
|
2008
|
0.75
|
|
69
|
Thigh abscess as an extension of psoas abscess: the first manifestation of perforated appendiceal adenocarcinoma: case report.
|
Wien Klin Wochenschr
|
2014
|
0.75
|
|
70
|
Deletion polymorphism of the angiotensin I-converting enzyme gene in elderly patients with coronary heart disease.
|
Coll Antropol
|
2007
|
0.75
|
|
71
|
[Familial hypercholesterolemia - do we think enough about this severe disease?].
|
Lijec Vjesn
|
2013
|
0.75
|
|
72
|
[Risk factors and carotid atherosclerosis in patients with transient ischaemic attack].
|
Lijec Vjesn
|
2004
|
0.75
|
|
73
|
[Croatian guidelines for nutrition in the elderly, part II--clinical nutrition].
|
Lijec Vjesn
|
2011
|
0.75
|
|
74
|
A view at the future--a dynamical, protocol-based and computationally intensive approach in cardiovascular risk assessment.
|
Coll Antropol
|
2010
|
0.75
|
|
75
|
[Table salt and hypertension--silent killers. Inform yourself and live longer. World day of hypertension 2009 in Croatia].
|
Lijec Vjesn
|
2009
|
0.75
|
|
76
|
Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats.
|
Arzneimittelforschung
|
2006
|
0.75
|
|
77
|
[Arterial hypertension and salt intake].
|
Acta Med Croatica
|
2010
|
0.75
|
|
78
|
[Effect of erythropoietin therapy on serum lipoprotein levels in patients on hemodialysis].
|
Lijec Vjesn
|
2002
|
0.75
|
|
79
|
[Croatian guidelines for nutrition in the elderly, part I].
|
Lijec Vjesn
|
2011
|
0.75
|
|
80
|
[Fabry disease--guidelines for diagnosis and management of adult patients].
|
Lijec Vjesn
|
2014
|
0.75
|